Abstract: The present invention is a self-disengaging pitot tube cover having a split cylinder configuration and an internal release mechanism, which is triggered by a temperature sensitive mechanism upon detecting a predetermined temperature so that the pitot tube cover separates and is released from the pitot tube at a predetermined temperature.

Abstract: A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.

Abstract: A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.

Abstract: A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.

Abstract: Techniques are used for adaptation of drug-administration parameters that control insulin delivery in a blood glucose control system. One technique provides long-term adaptation of a nominal basal infusion rate, adapting to longer-term changes in a patient's needs due to growth, illness, hormonal fluctuations, physical activity, aging, etc. Another technique provides adaptation of priming dose size at mealtimes for overall better glycemic control and also adapting to longer-term changes in a patient's needs. Adaptation calculations use a receding-horizon window of recent values of the adapted parameter. Doses of a counter-regulatory agent (e.g., glucagon) may also be delivered in response to information about estimated accumulation of exogenously infused insulin (subcutaneously, intramuscularly, intraperitoneally, or intravenously) and/or the effect insulin might have on glucose levels (blood glucose concentration or interstitial fluid glucose concentration).

Abstract: A glucose control system employs adaptation of a glucose target (set-point) control variable in controlling delivery of insulin to a subject to maintain euglycemia. The glucose target adapts based on trends in actual glucose level (e.g., measured blood glucose in the subject), and/or computed doses of a counter-regulatory agent such as glucagon. An adaptation region with upper and lower bounds for the glucose target may be imposed. Generally the disclosed techniques can provide for robust and safe glucose level control. Adaptation may be based on computed doses of a counter-regulatory agent whether or not such agent is actually delivered to the subject, and may be used for example to adjust operation in a bihormonal system during periods in which the counter-regulatory agent is not available for delivery.

Abstract: Techniques are used for adaptation of drug-administration parameters that control insulin delivery in a blood glucose control system. One technique provides long-term adaptation of a nominal basal infusion rate, adapting to longer-term changes in a patient's needs due to growth, illness, hormonal fluctuations, physical activity, aging, etc. Another technique provides adaptation of priming dose size at mealtimes for overall better glycemic control and also adapting to longer-term changes in a patient's needs. Adaptation calculations use a receding-horizon window of recent values of the adapted parameter. Doses of a counter-regulatory agent (e.g., glucagon) may also be delivered in response to information about estimated accumulation of exogenously infused insulin (subcutaneously, intramuscularly, intraperitoneally, or intravenously) and/or the effect insulin might have on glucose levels (blood glucose concentration or interstitial fluid glucose concentration).

Abstract: Techniques are used for adaptation of drug-administration parameters that control insulin delivery in a blood glucose control system. One technique provides long-term adaptation of a nominal basal infusion rate, adapting to longer-term changes in a patient's needs due to growth, illness, hormonal fluctuations, physical activity, aging, etc. Another technique provides adaptation of priming dose size at mealtimes for overall better glycemic control and also adapting to longer-term changes in a patient's needs. Adaptation calculations use a receding-horizon window of recent values of the adapted parameter. Doses of a counter-regulatory agent (e.g., glucagon) may also be delivered in response to information about estimated accumulation of exogenously infused insulin (subcutaneously, intramuscularly, intraperitoneally, or intravenously) and/or the effect insulin might have on glucose levels (blood glucose concentration or interstitial fluid glucose concentration).

Abstract: A disclosed tool coupling may include a clamp configured to hold a stirring tool and a shank connected to the clamp, the shank and the clamp sharing an axis of rotation, the clamp including a clamp housing defining an open interior region configured to receive the stirring tool and at least one adjustable fastener operably connected to the clamp housing, the fastener being configured to retain the stirring tool within the interior region.

Abstract: A method, system, and architecture for a font service and a software development kit (SDK) to provide developers with the means to design user-interfaces and content using a wide variety of font typefaces. The SDK may download a font from a font service as needed and activate the font to be rendered in the software application's user interface or other textual content within the application. A subscription service may be provided which comprises user account information or other data relating to permissions for one or more client devices to access one or more font files located in a font library. Further, one or more font files may be optimized according to an operating system in which the target application is operating and/or a screen resolution of a client device on which the target application is operating.

Abstract: Methods of modifying fibers, such as glass fibers, are disclosed. The modified fibers can be used, for example, in a lead acid battery.

Abstract: Methods of modifying fibers, such as glass fibers, are disclosed. The modified fibers can be used, for example, in a lead acid battery.

Abstract: Methods of modifying fibers, such as glass fibers, are disclosed. The modified fibers can be used, for example, in a lead acid battery.

Abstract: An electronic fuel injection control includes a main fuel control circuit, a transient enrichment control circuit temporarily increasing fuel flow as a result of increasing of a demand signal, and temperature compensation means non-linearly varying the effect of the enrichment control with engine temperature. The temperature compensation means preferably includes a temperature "window" detector which acts to increase the effect of the enrichment control whenever the engine temperature is between prescribed limits.

Abstract: An electronic fuel injection control includes a main fuel control circuit which operates to control fuel flow to the engine by controlling the duration of engine-synchronized fuel valve opening pulses in accordance with at least one engine parameter. An auxiliary pulse source is arranged to provide extra unsynchronized pulses to improve the acceleration characteristics of the control, such pulses being produced when the throttle is opened. A muting circuit is provided which operates for a fixed period following closing movement of the throttle, to prevent the auxiliary pulse source responding to throttle opening during said period. The muting circuit prevents excess fuelling during gear changes etc.

Abstract: An electronic fuel injection control includes a main control circuit which controls fuel flow to the engine by controlling the duration of pulses applied to fuel valves. In addition there is a transient fuel varying control including a differentiating circuit which differentiates the signal from a throttle position transducer. This differentiator controls a variable frequency clock which forms part of the main fuel control so that the pulse duration is lengthened or shortened for a given value of the engine parameter which controls the main fuel control according to the rate of increase or decrease of the throttle position signal.